Given that cell lines of all three molecular classes of CRC and with a different mutation status of KRAS, BRAF, PIK3CA, and TP53 were studied, these data suggest regorafenib efficiency as quite robust against specific molecular alterations. This evidence concerns the gene BRAF and colorectal carcinoma.